Details for New Drug Application (NDA): 020236
✉ Email this page to a colleague
The generic ingredient in SEREVENT is salmeterol xinafoate. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the salmeterol xinafoate profile page.
Summary for 020236
Tradename: | SEREVENT |
Applicant: | Glaxosmithkline |
Ingredient: | salmeterol xinafoate |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020236
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | AEROSOL, METERED;INHALATION | Strength | EQ 0.021MG BASE/INH | ||||
Approval Date: | Feb 4, 1994 | TE: | RLD: | No |
Expired US Patents for NDA 020236
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxosmithkline | SEREVENT | salmeterol xinafoate | AEROSOL, METERED;INHALATION | 020236-001 | Feb 4, 1994 | 4,992,474*PED | ⤷ Subscribe |
Glaxosmithkline | SEREVENT | salmeterol xinafoate | AEROSOL, METERED;INHALATION | 020236-001 | Feb 4, 1994 | 5,380,922 | ⤷ Subscribe |
Glaxosmithkline | SEREVENT | salmeterol xinafoate | AEROSOL, METERED;INHALATION | 020236-001 | Feb 4, 1994 | 5,126,375*PED | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription